- Home
- HOUR vs ALXO Comparison
HOUR vs ALXO Comparison
Compare HOUR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUR
- ALXO
- Stock Information
- Founded
- HOUR 2015
- ALXO 2015
- Country
- HOUR United States
- ALXO United States
- Employees
- HOUR N/A
- ALXO N/A
- Industry
- HOUR Catalog/Specialty Distribution
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- HOUR Consumer Discretionary
- ALXO Health Care
- Exchange
- HOUR Nasdaq
- ALXO Nasdaq
- Market Cap
- HOUR 79.1M
- ALXO 93.7M
- IPO Year
- HOUR 2022
- ALXO 2020
- Fundamental
- Price
- HOUR $1.82
- ALXO $1.57
- Analyst Decision
- HOUR
- ALXO Strong Buy
- Analyst Count
- HOUR 0
- ALXO 6
- Target Price
- HOUR N/A
- ALXO $3.30
- AVG Volume (30 Days)
- HOUR 52.5K
- ALXO 422.8K
- Earning Date
- HOUR 11-12-2025
- ALXO 11-07-2025
- Dividend Yield
- HOUR N/A
- ALXO N/A
- EPS Growth
- HOUR N/A
- ALXO N/A
- EPS
- HOUR 0.02
- ALXO N/A
- Revenue
- HOUR $138,441,228.00
- ALXO N/A
- Revenue This Year
- HOUR N/A
- ALXO N/A
- Revenue Next Year
- HOUR N/A
- ALXO N/A
- P/E Ratio
- HOUR $90.82
- ALXO N/A
- Revenue Growth
- HOUR N/A
- ALXO N/A
- 52 Week Low
- HOUR $1.10
- ALXO $0.40
- 52 Week High
- HOUR $6.90
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- HOUR 32.58
- ALXO 48.51
- Support Level
- HOUR $2.11
- ALXO $1.49
- Resistance Level
- HOUR $2.15
- ALXO $1.90
- Average True Range (ATR)
- HOUR 0.17
- ALXO 0.13
- MACD
- HOUR -0.04
- ALXO -0.04
- Stochastic Oscillator
- HOUR 1.27
- ALXO 19.51
About HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.